| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/01/2007 | WO2007023880A1 Chemokine production inhibitor |
| 03/01/2007 | WO2007023754A1 DRUG CONTAINING FBPase INHIBITOR |
| 03/01/2007 | WO2007023495A2 Method for production of single- and multi-layer microcapsules |
| 03/01/2007 | WO2007023172A2 Protein composition for treating a physiologically caused, clinically normal increased need for protein |
| 03/01/2007 | WO2007003961A3 Gpcr agonists |
| 03/01/2007 | WO2006129193A3 Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| 03/01/2007 | WO2006122186A3 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
| 03/01/2007 | US20070049735 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070049620 Cyclic tertiary amine compound |
| 03/01/2007 | US20070049600 Pteridinones as kinase inhibitors |
| 03/01/2007 | US20070049594 Novel compounds and compositions as cathepsin inhibitors |
| 03/01/2007 | US20070049535 Preventive/remedy for diabetic complications using oligopeptide |
| 03/01/2007 | US20070049532 Selecting by phage display a peptide that binds to nerve growth factor (NGF), and preparing a fusion protein with an Fc domain; biological half-life increases |
| 03/01/2007 | US20070049515 Therapeutic agent for diabetes containing insulin resistance improving agent |
| 03/01/2007 | US20070048846 Detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells |
| 03/01/2007 | US20070048804 Methods of detecting cytokine receptor zcytor19 ligand |
| 03/01/2007 | US20070048799 hematopoietic cytokine receptor polypeptide encoded by nucleotides equences for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs |
| 03/01/2007 | US20070048319 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070048311 ANTI-INTERFERON-alpha ANTIBODIES |
| 03/01/2007 | US20070048221 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070048220 Antibodies that bind both bcma and taci |
| 03/01/2007 | DE19633446B4 Arzneimittel mit lipidsenkender Wirkung Drugs with lipid-lowering effect |
| 03/01/2007 | CA2621164A1 Derivative having ppar agonistic activity |
| 03/01/2007 | CA2620026A1 Method for production of single- and multi-layer microcapsules |
| 03/01/2007 | CA2619770A1 Phenylpyridone derivative |
| 03/01/2007 | CA2619491A1 Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| 03/01/2007 | CA2619426A1 Exendin for treating diabetes and reducing body weight |
| 02/28/2007 | EP1757937A2 Antagonists of HMG1 for treating inflammatory conditions |
| 02/28/2007 | EP1757621A2 Compositions and methods for the treatment and diagnosis of immune disorders |
| 02/28/2007 | EP1757619A2 Osteoprotegerin in milk |
| 02/28/2007 | EP1757614A1 Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases |
| 02/28/2007 | EP1757606A1 Xanthinderivatives, preparation thereof and their use as medical agents |
| 02/28/2007 | EP1757602A1 Vla-4 inhibitor |
| 02/28/2007 | EP1757600A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 02/28/2007 | EP1757596A1 Tyrosine derivatives substituted by n-phenylacryloyl as agonists of hppar alpha and hppar gama |
| 02/28/2007 | EP1757594A1 Quinazoline derivative |
| 02/28/2007 | EP1757590A1 Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof |
| 02/28/2007 | EP1757589A1 Amorphous phase of a substituted pyrazoline, its preparation and use as medicament |
| 02/28/2007 | EP1757302A1 Adiponectin expression inducer and utilization of the same |
| 02/28/2007 | EP1757293A1 Bh4-responsive hyperphenylalaninemia remedies |
| 02/28/2007 | EP1757291A2 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
| 02/28/2007 | EP1757289A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis |
| 02/28/2007 | EP1757287A1 Pharmaceutical composition for prevention or treatment of lipid metabolism disorder |
| 02/28/2007 | EP1756140A1 Selective separation or extraction of steroidal glycosides by supercritical fluid extraction using carbon dioxide |
| 02/28/2007 | EP1756107A2 Aryl-substituted piperazine derivatives |
| 02/28/2007 | EP1756100A1 Salt of phosphoric acid with 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)-ethoxy] benzy] thiazolidin-2,4-dione and a method of its preparation |
| 02/28/2007 | EP1756096A1 Indolyl derivatives as liver-x-receptor modulators |
| 02/28/2007 | EP1756084A2 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 02/28/2007 | EP1756081A1 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors |
| 02/28/2007 | EP1756078A1 Phenylsulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase inhibitors |
| 02/28/2007 | EP1756076A1 Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| 02/28/2007 | EP1756053A1 Process for the preparation of atorvastatin |
| 02/28/2007 | EP1756051A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 02/28/2007 | EP1756025A1 Sulfonamide derivatives |
| 02/28/2007 | EP1755656A1 Enzymes for pharmaceutical use |
| 02/28/2007 | EP1755611A1 Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| 02/28/2007 | EP1755604A2 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 02/28/2007 | EP1755593A1 Naphthaline derivatives useful as histamine-3-receptor ligands |
| 02/28/2007 | EP1755587A1 Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof |
| 02/28/2007 | EP1755580A1 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids |
| 02/28/2007 | EP1755573A1 Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
| 02/28/2007 | EP1755565A2 Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid |
| 02/28/2007 | EP1755401A1 Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport |
| 02/28/2007 | EP1482951B8 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| 02/28/2007 | EP1416812B1 Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level |
| 02/28/2007 | EP1415987B1 Nitrogenous aromatic ring compounds as anti cancer agents |
| 02/28/2007 | EP1387843B1 Method for obtaining pioglitazone as an antidiabetic agent |
| 02/28/2007 | EP1370531B1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| 02/28/2007 | EP1368094B1 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo- 1,5-a|-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 02/28/2007 | EP1301201B1 Treatment of glycogen storage disease type ii |
| 02/28/2007 | EP1265606B9 Cell adhesion inhibitors |
| 02/28/2007 | EP1233013B1 Novel phenylalanine derivatives |
| 02/28/2007 | EP1151756B1 Kit comprising polyacrylamide gel for forming a capsule in the tissue of a mammal organism and allogenic or xenogenous cells of an animal, method for therapy of oncological diseases and the diabetes mellitus |
| 02/28/2007 | EP1083915B1 Compositions comprising molybdenum for enhancing protein anabolism and detoxification |
| 02/28/2007 | CN1922183A Nitrogenous fused heteroaromatic ring derivative |
| 02/28/2007 | CN1922171A Pyrimidine derivative |
| 02/28/2007 | CN1922159A Benzamide derivatives and their use as glucokinase activating agents |
| 02/28/2007 | CN1922151A Substituted azole derivatives, compositions, and methods of use |
| 02/28/2007 | CN1922139A Bicyclic amide derivatives |
| 02/28/2007 | CN1921881A Use of hydroxylated amino acids for treating diabetes |
| 02/28/2007 | CN1921875A Beverage and medicine having bamboo extractive as main component |
| 02/28/2007 | CN1921871A Physiologically active composition and process for producing the same |
| 02/28/2007 | CN1921869A Lipase activity inhibitor containing high-molecular weight polyphenol fraction, tea extract and process for producing the same |
| 02/28/2007 | CN1921860A Hyperlipemia therapeutic agent |
| 02/28/2007 | CN1921849A Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
| 02/28/2007 | CN1921843A Retinoic acid-containing remedy for diabetes |
| 02/28/2007 | CN1919853A Phosphor isoquinolinone, derivative, synthesis method and use thereof |
| 02/28/2007 | CN1919338A Insulin liquid formulations for nose administration |
| 02/28/2007 | CN1919337A Insulin powder nose inhalant and preparing process thereof |
| 02/28/2007 | CN1919335A Albumen powder capsule |
| 02/28/2007 | CN1919315A Diabetes curative effect tea |
| 02/28/2007 | CN1919283A Method for treating diabetes by using astragalus root and radix rehmanniae for heat clearing and detoxicating |
| 02/28/2007 | CN1919277A Application of pharmaceutical composition in the process for preparing medicine of enhancing insulin sensitivity |
| 02/28/2007 | CN1919229A Bauhinia hupehara C. extract for the treatment of diabetes and obesity |
| 02/28/2007 | CN1919225A Application of cultured saussurea medusa and extract thereof in preparation of medicine for treating II type diabetes and its complications |
| 02/28/2007 | CN1919214A Monascus soft capsule and its preparation method |
| 02/28/2007 | CN1919213A Monascus pellet and its preparing method |
| 02/28/2007 | CN1919207A Gariic and medlar capsule |
| 02/28/2007 | CN1919206A Vitexin injection and oral administration preparation thereof |
| 02/28/2007 | CN1919201A Compounds and methods for therapeutic intervention in preventing diabetic complications |